Events & News

Events & News

Latest Innovations

Optimizing Hydroxyl Groups: The Tertiary Alcohol Advantage in Medicinal Chemistry

15 July 2025

Latest Innovations

Recommended Products View More

Previous research has established that the strategic substitution of a hydrogen atom with a hydroxyl group (H-to-OH) effectively diminishes molecular lipophilicity, enhances aqueous solubility, and attenuates hERG inhibition. Notwithstanding these advantageous properties, hydroxyl groups (OH) are not universally preferred in pharmaceutical design. This selectivity arises because in primary and secondary alcohols, the OH moiety constitutes a metabolic vulnerability, susceptible to oxidative processes and glucuronidation reactions. Furthermore, hydroxyl groups may adversely affect cell membrane permeability parameters. Conversely, tertiary alcohols (3° ROH) frequently demonstrate superior metabolic profiles. This enhancement stems from the structural configuration of 3° ROH, where oxidation at the carbon-hydroxyl junction is sterically hindered, and adjacent alkyl substituents provide protective steric effects to the OH group, thereby reducing susceptibility to glucuronidation and mitigating permeability constraints.

Synthetic pharmaceutical drugs containing a 3° ROH group are typically designed with the deliberate incorporation of this structural motif within their pharmacophore. Consequently, the mechanistic roles and therapeutic advantages conferred by the 3° ROH structural element in de novo-designed pharmaceutical compounds have been comprehensively elucidated (Figure 1).

Figure 1. The mechanistic role and therapeutic advantages of approved de novo-designed pharmaceuticals incorporating 3° ROH structural motifs

Literature Evidence of Matched Molecular Pairs Leading to 3° ROH
·Enhancement of Target-Specific Potency

In the paper titled "Tertiary Alcohol: Reaping the Benefits but Minimizing the Drawbacks of Hydroxy Groups in Drug Discovery" published on Journal of Medicinal Chemistry, Dr. Debora Chiodi and Dr. Yoshihiro Ishihara comprehensively examined the strategic implementation of hydroxyl (OH) groups or their conversion to tertiary alcohols (3° ROH) for enhancing target-specific pharmaceutical potency during drug discovery processes. Through multiple structure-activity relationship analyses, this study elucidates the mechanistic effects of such structural modifications on pharmacological activity, encompassing applications in the development of therapeutic agents for hypertension, asthma, oncological conditions, and epilepsy management.

·Solubility Enhancement

The incorporation of hydroxyl functionalities generally reduces compound hydrophobicity, thereby enhancing aqueous solubility. This phenomenon is particularly pronounced in non-aromatic molecular systems. The steric hindrance characteristic of 3° ROH structures provides protective effects for the hydroxyl moiety, potentially modulating its interactions with water molecules, thus maintaining or improving solubility parameters under specific conditions. Additionally, the strategic introduction of 3° ROH structures can mitigate challenges associated with metabolic instability and transmembrane permeability.

·Permeability and Efflux Considerations

The introduction of hydroxyl groups typically reduces membrane permeability; however, 3° ROH structures partially shield hydroxyl functionalities through steric effects, thereby attenuating adverse impacts on permeability parameters. Hydroxyl groups may potentiate drug efflux mechanisms, whereas 3° ROH structures can reduce efflux tendencies through steric hindrance or the formation of intramolecular hydrogen bonds. Notably, the efficacy of this strategy is context-dependent, influenced by molecular structural characteristics and microenvironmental factors. Permeability and solubility parameters frequently present optimization challenges requiring careful equilibration during pharmaceutical design processes.

·Metabolic Stability: In Vitro Clearance Profiles

3° ROH structural elements significantly enhance pharmaceutical metabolic stability through inhibition of oxidative metabolic pathways and reduction of glucuronidation reactions. This structural modification holds considerable value in pharmaceutical design, particularly in scenarios necessitating enhanced compound stability and reduced metabolic pathway diversity. While 3° ROH structures improve metabolic stability, establishing an optimal balance between lipophilicity and metabolic stability remains essential to ensure favourable overall pharmacokinetic properties of the therapeutic agent.

·ADME Parameters: Bioavailability and Systemic Exposure

3° ROH structural elements confer significant advantages in enhancing pharmaceutical bioavailability and systemic exposure. The underlying mechanisms include: reduction of molecular hydrophobicity (cLogP) through improved solubility and permeability parameters; diminished metabolic clearance through steric protection of hydroxyl functionalities, thereby reducing oxidative metabolism and glucuronidation reactions; and enhanced bioavailability through attenuation of first-pass metabolism effects, resulting in increased effective drug concentrations in vivo (Figure 2).

Figure 2. A) Structure of clinical candidate OSI-906

More product details: A139562: Linsitinib (OSI-906) is a potent, selective, and orally bioavailable dual inhibitor of the IGF-1 receptor and insulin receptor (IR) with IC50s of 35 nM and 75 nM, respectively.

·Off-Target Interactions: hERG, Cytochrome P450, and Pregnane X Receptor

The incorporation of hydroxyl (OH) functionalities can attenuate hERG inhibition, reduce cytochrome P450 enzyme inhibition, and diminish pregnane X receptor activation. Due to their distinctive steric properties, 3° ROH structures can decrease binding affinity for hERG channels, cytochrome P450 enzyme systems, and PXR receptors, thereby reducing the risk of these off-target interactions. Compared to primary (1° ROH) and secondary (2° ROH) alcohols, tertiary alcohols demonstrate superior efficacy in minimizing off-target activities, primarily attributable to the reduced recognition and binding of the sterically hindered hydroxyl functionality by cellular membrane systems, cytochrome P450 enzymes, and PXR receptors.

Follow us on LinkedIn and stay at the forefront of Science.

References

[1]Chiodi D, Ishihara Y. Tertiary Alcohol: Reaping the Benefits but Minimizing the Drawbacks of Hydroxy Groups in Drug Discovery. J. Med. Chem. 2025, 68(8), 7889-7913.

[2]Cai Y., Shi S.-L. Enantioconvergent arylation of racemic secondary alcohols to chiral tertiary alcohols enabled by nickel/N-heterocyclic carbene catalysis. J. Am. Chem. Soc. 2021, 143(31), 11963−11968.

[3]Stymiest J. L., Bagutski V., French R. M., et al. Enantiodivergent conversion of chiral secondary alcohols into tertiary alcohols. Nature 2008, 456, 778−783.

Prev: Modular Arene Functionalization by Differential 1,2-Diborylation

Next: Cost-effective and High-Performance Ionizable Lipids for mRNA-LNP Vaccines: One-Pot Ugi-4CR Strategy and Preclinical Evaluation